Acrivon Therapeutics (ACRV) Change in Accured Expenses (2021 - 2026)

Acrivon Therapeutics (ACRV) has reported Change in Accured Expenses for 6 consecutive years, with -$3.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 51.72% year-over-year to -$3.4 million; the TTM figure through Mar 2026 stood at $265000.0 (down 89.43% YoY), while the FY2025 annual figure was -$3.4 million, down 141.8% from the prior year.
• Change in Accured Expenses eased to -$3.4 million in Q1 2026 per ACRV's latest filing, from -$481000.0 in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $3.5 million in Q3 2024 and bottomed at -$7.0 million in Q1 2025.
• Historically, Change in Accured Expenses has averaged $434235.3 across 5 years, with a median of $1.0 million in 2023.
• Annual changes were most pronounced in 2024 — Change in Accured Expenses soared 205.77% — and 2025, when it plunged 372.38%.
• Acrivon Therapeutics' Change in Accured Expenses stood at $1.5 million in 2022, then plunged by 32.07% to $1.0 million in 2023, then jumped by 205.77% to $3.2 million in 2024, then tumbled by 115.13% to -$481000.0 in 2025, then slumped by 602.29% to -$3.4 million in 2026.
• Business Quant data shows ACRV's Change in Accured Expenses at -$3.4 million in Q1 2026, -$481000.0 in Q4 2025, and $2.0 million in Q3 2025.